DUBLIN, Sept. 17, 2021 /PRNewswire/ -- Gain comprehensive access to over 850 immunology deal records from this report "Global Immunology Partnering 2014-2021: Deal Trends, Players and Financials" that has been added to ResearchAndMarkets.com's offering.
This report provides a full collection of Immunology disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
- Trends in Immunology partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Immunology partnering agreement structure
- Immunology partnering contract documents
- Top Immunology deals by value
- Most active Immunology dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.
The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Immunology dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Immunology dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Immunology deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Immunology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Immunology deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Immunology partnering deals by specific Immunology target announced since 2014. The chapter is organized by specific Immunology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Immunology partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Immunology partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Immunology technologies and products.
Report Scope
The report is intended to provide the reader with an in-depth understanding and access to Immunology trends and structure of deals entered into by leading companies worldwide.
Global Immunology Partnering 2014 to 2021 includes:
- Trends in Immunology dealmaking in the biopharma industry since 2014
- Analysis of Immunology deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Immunology deal contract documents
- Comprehensive access to over 850 Immunology deal records
- The leading Immunology deals by value since 2014
- Most active Immunology dealmakers since 2014
The report includes deals for the following indications: AIDS, Allergy, Anaphylactic shock, Graft versus host disease, Inflammation, Other autoimmune, Scleroderma, Systemic lupus erythematosus, plus other immunology indications.
In Global Immunology Partnering 2014 to 2021, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Immunology Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 850 immunology deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Immunology dealmaking
2.1. Introduction
2.2. Immunology partnering over the years
2.3. Immunology partnering by deal type
2.4. Immunology partnering by industry sector
2.5. Immunology partnering by stage of development
2.6. Immunology partnering by technology type
2.7. Immunology partnering by therapeutic indication
Chapter 3 -Financial deal terms for Immunology partnering
3.1. Introduction
3.2. Disclosed financials terms for Immunology partnering
3.3. Immunology partnering headline values
3.4. Immunology deal upfront payments
3.5. Immunology deal milestone payments
3.6. Immunology royalty rates
Chapter 4 - Leading Immunology deals and dealmakers
4.1. Introduction
4.2. Most active in Immunology partnering
4.3. List of most active dealmakers in Immunology
4.4. Top Immunology deals by value
Chapter 5 - Immunology contract document directory
5.1. Introduction
5.2. Immunology partnering deals where contract document available
Chapter 6 - Immunology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Immunology therapeutic target
Appendices
Companies Mentioned
- 4D Pharma
- 23andMe
- A*STAR Agency for Science
- Technology and Research
- A*STAR Genome Institute of Singapore
- A*STAR' Institute of Molecular and Cell Biology
- Aarhus University Hospital
- AB Biosciences
- Abbott Laboratories
- Abbvie
- Abcam
- Abide Therapeutics
- Abingworth Management
- ABL Bio
- Ablynx
- Abpro
- Abreos Biosciences
- Abzena
- AC Immune
- Actelion
- ActoGeniX
- Adamis Pharmaceuticals
- Adaptive Biotechnologies
- Aduro BioTech
- Advanz Pharma
- Advaxis
- Aerocrine
- Affibody
- AGC Biologics
- Agenus Bio
- AIDS Clinical Trials Group
- AIDS Foundation of Chicago
- Aimmune Therapeutics
- AirWare Labs
- Akers Biosciences
- Akeso Biopharma
- Akrevia Therapeutics
- Akriveia Therapeutics
- Aldeyra Therapeutics
- Alector
- Alexion Pharmaceuticals
- ALK-Abello
- Allakos
- Allen Institute for Brain Science
- AllerGenis
- Allergopharma
- Alliance for Biosecurity
- Alliance for Lupus Research
- Allied-Bristol Life Sciences
- Alloksys Life Sciences
- Alpine Immune Sciences
- AltaVoice
- Alvotech
- Alzheimer's Association
- AM-Pharma
- Amal Therapeutics
- Amegabiotech
- American Diabetes Association
- Amgen
- AMPEL BioSolutions
- Amunix
- Angiocrine Bioscience
- ANI Pharmaceuticals
- Annapurna Therapeutics
- Anokion
- Anthera Pharmaceuticals
- Antibe Therapeutics
- Apeiron Biologics
- Apocell
- Applied BioMath
- Aptevo Therapeutics
- Aqilion
- Aquila BioMedical
- Aralez Pharmaceuticals
- Aratana Therapeutics
- Arbele
- Arbutus
- Archer Daniels Midland Company
- Arcutis
- Arena Pharmaceuticals
- arGEN-X
- argenx
- Ario Pharma
- Array Biopharma
- Arrien Pharmaceuticals
- Artelo Biosciences
- Asana Biosciences
- AskAt
- Aslan Pharma
- Astellas Pharma
- Astion Pharma
- AstraZeneca
- Atara Biotherapeutics
- ATGen Global
- Atreca
- Aurinia Pharmaceuticals
- Avacta
- Avactis Biosciences
- Avalere Health
- Avalon GloboCare
- Avid Bioservices
- Avidity Biosciences
- Avillion
- Axela
- AyoxxA Biosystems
- Bausch & Lomb
- Baxalta
- Baxter International
- Bayer Animal Health
- Baylor College of Medicine
- Beactica
- Beckman Coulter
- BeiGene
- Bellicum Pharmaceuticals
- Berg
- Berkeley Lights
- Bertin Pharma
- Bial
- Bill and Melinda Gates Foundation
- Bina Technologies
- Bio-Cancer Treatment International
- Bio-Path
- BioBright
- BioCad Holding
- bioCSL
- Biocytogen
- Biogen
- Biohaven Pharmaceutical Holding
- Bioject Medical Technologies
- BiolineRX
- BioMed X Innovation Center
- Biomunex Pharmaceuticals
- BioRap Technologies
- BioSense Global
- Biosortia Pharmaceuticals
- Biotest
- Biotest Pharmaceuticals
- BirchBioMed
- Black AIDS Institute
- Bleeding Disorders Foundation
- Bloom Burton
- BlueRock Therapeutics
- Boehringer Ingelheim
- Botanisol
- Bpifrance
- Breathe Active
- Brickell Biotech
- Brigham and Women's Hospital
- Brii Biosciences
- Bristol-Myers Squibb
- Broad Institute
- Buck Institute for Age Research
- C4X Discovery
- Cadila Pharmaceuticals
- Caelum Biosciences
- Calico
- California Institute for Regenerative Medicine
- Calypso Biotech
- Canadian Council
- Canadian Institutes of Health Research
- Cancer Genetics
- Cancer Research Institute
- Cardinal Partners
- CareFirst BlueCross BlueShield
- Casebia Therapeutics
- Celgene
- Cellgen Diagnostics
- Cell Mogrify
- CellSight Technologies
- Center for iPS Cells Research and Application
- Centers for Disease Control and Prevention
- Centogene
- Central Institute for Experimental Animals
- Centre Leon Berard
- Centre National de la Recherche Scientifique
- Centurion
- Charles River Laboratories
- Checkpoint Therapeutics
- Children's Hospital Boston
- Chong Kun Dang
- Chr Hansen
- ChromaDex
- Chugai Pharmaceutical
- Chugai Pharma Marketing
- Cigna Healthcare
- Cipher Pharmaceuticals
- Circassia
- Circulogene
- City of Hope
- Coherus Biosciences
- Columbia University
- Commense
- Complix
- Compugen
- ConsortiaTX
- Corbin Therapeutics
- Corbus Pharmaceuticals
- Crescendo Biologics
- CRISPR Therapeutics
- Cristal Therapeutics
- Crown Bioscience
- Crystal Bioscience
- CSL Behring
- CSPC Pharmaceutical Group
- Cue Biopharma
- Curable
- Curetis
- CureVac
- Cureveda
- Cyclenium Pharma
- CyDex
- Cynata Therapeutics
- Cynvenio
- Cystic Fibrosis Foundation Therapeutics
- Cytobank
- CytomX Therapeutics
- CytoReason
- Daiichi Sankyo
- Dako
- Dana-Farber Cancer Institute
- Dartmouth College
- DBV Technologies
- DecImmune Therapeutics
- Denali Therapeutics
- DendroCyte
- Department of Defense
- Devonian Health Group
- DiaCarta
- Diatheva
- DNAtrix
- DNX Biopharmaceuticals
- Dong-A ST
- Dragonfly Therapeutics
- Duke-NUS Graduate Medical School Singapore
- Duke University
- Eastar Industries
- Eddingpharm
- Eisai
- Eisai Inc
- Eli Lilly
- Elpis Biomed
- ElsaLys Biotech
- Elton John AIDS Foundation
- EMD Serono
- Emerge Health
- Emory University
- Enamine
- EnBiotix
- Encycle Therpaeutics
- Endo Pharmaceuticals
- Enesi Pharma
- Ensemble Therapeutics
- Enterome Bioscience
- Enumeral Biomedical
- EpimAb Biotherapeutics
- Epirus Biopharmaceuticals
- Epivax
- Essex Bio-Technology
- eTheRNA immunotherapies
- Eton Pharmaceuticals
- Eurofins Scientific
- European Bioinformatics Institute
- European Union
- Evelo Biosciences
- Everest Medicines
- Evotec
- Ewopharma
- Exagen Diagnostics
- ExeGi Pharma
- ExScientia
- f-Star
- Feinstein Institute for Medical Research
- Feldan Therapeutics
- Ferring Pharmaceuticals
- Fibrocell Science
- Five Prime Therapeutics
- Fluidigm
- Folia Biotech
- Food and Drug Administration (FDA)
- Foundation Medicine
- Fred Hutchinson Cancer Research Center
- French Alternative Energies and Atomic Energy Commission
- French National Genotyping Center
- FSD Pharma
- Fuji Pharma
- G2B Pharma
- Galapagos
- GammaDelta Therapeutics
- Gateway Hemophilia Association
- GC LabCell
- GE Healthcare
- Gencia Biotech
- GeneQuantum Healthcare
- Genethon
- Genfit
- Genmab
- Genomic Testing Cooperative
- Georgetown University
- George Washington University
- GeoVax
- Gesynta Pharma
- Gilead Sciences
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- Global Centers for Therapeutic Innovation
- Gradalis
- Great Ormond Street Hospital (GOSH)
- Gritstone Oncology
- Grunenthal
- Guardant Health
- Hadasit Medical Research Services and Development
- Halfpenny Technologies
- HalioDx
- Halozyme Therapeutics
- HanAll Pharmaceuticals
- Hanmi Pharmaceutical
- Harbour Biomed
- Harvard University
- Heat Biologics
- HemispheRx Biopharma
- Hemophilia Foundation of Southern California
- Heptares Therapeutics
- HiFiBio
- Highline Therapeutics
- Hob Diagnostics
- Hoffmann La Roche
- Hookipa Biotech
- Horizon Pharma plc
- Hospices Civils de Lyon
- Hospira
- Hospital for Special Surgery
- iBio
- Icahn School of Medicine at Mount Sinai
- ICM
- Idera Pharmaceuticals
- Igenica
- ILTOO Pharma
- Imab
- ImaginAb
- IMIDomics
- Immatics Biotechnologies
- Immatics US
- Immugenyx
- ImmunArray
- Immune Deficiency Foundation
- Immune Design
- Immuneed
- Immune Pharmaceuticals
- ImmuNext
- ImmunoChina Pharmaceuticals
- Immunomedics
- Immunomic
- Immunovia
- Immunscape
- ImmuPharma
- Incyte
- InDex Pharmaceuticals
- Indigo Biosciences
- InflamaCORE
- InMed Pharmaceuticals
- Innate Pharma
- Innovate UK
- Innovative Genomics Initiative (IGI)
- Innovative Targeting Solutions
- Innovus Pharmaceuticals
- Inovalon
- Inovio Pharmaceuticals
- Inserm Transfert
- Institut Curie
- Institute for Bioscience and Biotechnology Research
- Institute for Research in Immunology and Cancer - Commercialization of Research
- Institute for the Promotion of Innovation by Science and Technology in Flanders
- Institute of Child Health
- Institut Pasteur
- Institut Pasteur of Shanghai at the Chinese Academy of Sciences
- Intarcia Therapeutics
- International AIDS Vaccine Initiative
- Intrexon
- Ionis Pharmaceuticals
- Ipca Laboratories
- iReceptor Plus
- ISA Scientific
- ISIS Innovation
- IsoPlexis
- iTeos Therapeutics
- Itus
- J-Network
- Janssen Biotech
- Janssen Diagnostics
- Janssen Research & Development
- Janus Pharmaceuticals
- Japan Tobacco
- Jazz Pharmaceuticals
- JDP Therapeutics
- Jeffrey Modell Foundation
- Jiangsu Chia Tai Tianqing Pharmaceutical
- Jiangsu Hengrui Medicine
- Johns Hopkins Kimmel Cancer Center
- Johns Hopkins Medicine (JHM)
- Johns Hopkins University
- Johnson & Johnson
- Johnson & Johnson Innovation
- Juno Therapeutics
- Kaken Pharmaceutical
- Kamada
- Karyopharm Therapeutics
- Kedrion Biopharma
- Keio Gijuku University
- Kennedy Trust For Rheumatology Research
- Kiadis Pharma
- Kimberly-Clark
- Kineta
- King's College Hospital
- Kissei Pharmaceutical
- Kite Pharma
- Klaria
- Knight Therapeutics
- Kymab
- Lannett
- Laurel Venture Capital
- Lead Discovery Center
- Lead Pharma
- Lee's Pharmaceutical
- LegoChem Biosciences
- Leiden University
- Leidos
- LEO Pharma
- Les Laboratoires Servier
- Leukemia & Lymphoma Society
- LG Life Sciences
- LifeArc
- LifeMax Laboratories
- Ligand Pharmaceuticals
- Lipum
- Lonza
- Lubeck Institute of Experimental Dermatology
- Luminex
- Lupin
- Lupus Foundation of America (LFA)
- Lupus Research Alliance
- Lupus Research Institute
- Lupus Therapeutics
- Luye Pharma Group
- MaaT Pharma
- mAbXience
- Macrogenics
- Macrophage Pharma
- Mallinckrodt Pharmaceuticals
- Mariel Therapeutics
- Massachusetts General Hospital
- Massachusetts Institute of Technology
- Max-Planck
- Maxcyte
- Mayo Clinic
- McGill University
- MD Anderson Cancer Center
- Medical Research Council
- Medical University of South Carolina
- Medical University South Carolina
- Medidata Solutions
- MedImmune
- Memorial Sloan Kettering Cancer Center
- Merck and Co
- Merck KGaA
- Merck Sharpe & Dohme
- Merus
- Metrion Biosciences
- Microdrop
- Microsoft
- Midatech
- MilliporeSigma
- MIODx
- Mitra Biotech
- Mitsubishi Tanabe Pharma
- ModiQuest Research
- Monash University
- MorphoSys
- Mor Research Applications
- Mount Sinai Health System
- Mount Sinai Medical Center
- Mount Tam Biotechnologies
- Mundipharma
- Munich Technical University
- Mustang Bio
- My Brother's Keeper
- Mylan Pharmaceuticals
- NanoPass Technologies
- NantWorks
- Napo Pharmaceuticals
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- National Institute of Dental and Craniofacial Research (NIDCR)
- National Institutes of Health
- Nature Technology
- Nektar Therapeutics
- Neostell
- Neovacs
- Neovii Pharmaceuticals
- Neptune Technologies & Bioressources
- Nestle Health Science
- NeuClone
- Neumedicines
- NeuroCycle Therapeutics
- NeuroVive Pharmaceutical
- Newsoara Biopharma
- New York University
- New York University School of Medicine
- Neximmune
- NextCure
- Nexvet
- Nimbus Therapeutics
- Ningbo Tai Kang Medical Technology
- NJCTTQ
- Nodality
- Northwestern University
- Novalere
- Novant Health
- Novartis
- NovaSAID
- NovImmune
- Novo Nordisk
- Novozymes
- Nuevolution
- Numab
- Nurix
- Nuvo Pharmaceuticals
- NYU Langone Medical Center
- Ocata Therapeutics
- Oklahoma Medical Research Foundation
- Omeros
- Oncobiologics
- Oncologie
- OncoQuest
- OncoSec Medical
- Ono Pharmaceutical
- OraSure Technologies
- Orca Pharmaceuticals
- Orchard Therapeutics
- Orexo
- Ortho-Clinical Diagnostics
- Osaka University
- OSE Immunotherapeutics
- OSEO
- Ospedale San Raffaele
- Owlstone Medical
- Oxford University Hospitals NHS Trust
- Padlock Therapeutics
- Pandion Therapeutics
- Panther Biotechnology
- Paragon Bioservices
- PatientsLikeMe
- Peking University
- Pelican Therapeutics
- Pendopharm
- PeptiDream
- Perelman School of Medicine
- Pfizer
- PharmEste
- Pharmstandard
- Pharnext
- Philogen
- Pieris
- Pierre Fabre
- Pinnacle Clinical Research Center
- Pionyr Immunotherapeutics
- Plasticell
- Pluristem Therapeutics
- Potenza Therapeutics
- Precision BioSciences
- Prestizia
- PreventionGenetics
- Principia Biopharma
- ProBioGen
- Project Inform
- Protagen
- Prota Therapeutics
- ProtoKinetix
- Provention Bio
- Proximagen Group
- Pulmatrix
- Purdue Pharma
- PureTech Health
- Pyramid Biosciences
- Qiagen
- Quartet Medicine
- Queensland Institute of Medical Research (QIMR)
- Quest PharmaTech
- R-Tech Ueno
- Rabin Medical Center (Beilinson Hospital)
- Ragon Institute
- RedHill Biopharma
- Regeneron Genetics Center
- Regeneron Pharmaceuticals
- RespiVert
- Rheonix
- RMX Biopharma
- Roche
- Rogne Bioscience
- Roivant Sciences
- Rosetta Genomics
- Roxall
- S-TARget
- Salix Pharmaceuticals
- Sangamo BioSciences
- Sanofi
- Sanofi-Aventis
- Saol Therapeutics
- Sartorius Stedim Biotech
- SATT Lutech
- Scholar Rock
- SciCann Therapeutics
- Science Exchange
- Scienion
- Sciex
- Scleroderma Research Foundation
- Scripps Research Institute
- Sean N Parker Center for Allergy Research
- Seattle Children's Hospital
- Seattle Childrens Research Institute
- Seattle Genetics
- Second Genome
- Selecta Biosciences
- Selexis
- Sementis
- SenzaGen
- Seqirus
- Serametrix
- Seres Therapeutics
- Serum Institute of India
- Sevion Therapeutics
- Shanghai Model Organisms Center
- Shin Nippon Biomedical Laboratories
- Shire Laboratories
- Sigma-Tau
- Sigmoid
- Simbec Research
- Simcere Pharmaceuticals
- Sirona Biochem
- SomaLogic
- Sorrento Therapeutics
- Sosei
- Splicos
- SQI Diagnostics
- St. Jude Children's Research Hospital
- Stallargenes
- Stanford University
- Stanford University School of Medicine
- Stellar Biotechnologies
- Stony Brook University
- Stryker
- Sutro Biopharma
- Swedish Orphan Biovitrum
- Swiss Commission for Technology and Innovation
- Symbiotix Biotherapies
- Symphogen
- Takeda Pharmaceutical
- Tango Therapeutics
- Targeted Medical Pharma
- Teijin
- Tel Aviv Sourasky Medical Center
- Telix Pharmaceuticals
- TeneoBio
- Tennessee Hemophilia
- Tessa Therapeutics
- Tetra Bio-Pharma
- Tetragenetics
- Teva Pharmaceutical Industries
- TG Therapeutics
- The Elizabeth Taylor AIDS Foundation
- The Hospital for Sick Children
- The International AIDS Vaccine Initiative
- The Myositis Association
- The Parker Institute For Cancer Immunotherapy
- Theradiag
- Thermo Fisher Scientific
- Thomas Jefferson University
- Tiziana Life Sciences
- Tizona Therapeutics
- T Med
- Topas Therapeutics
- Tow Foundation
- Traaser
- TransBio
- Transgene
- Transimmune
- Triumvira Immunologics
- True Diagnostics
- True North Therapeutics
- Tsinghua University
- Turgut Ilaclari
- Twist Bioscience
- TxCell
- UCB
For more information about this report visit https://www.researchandmarkets.com/r/3bsutc
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article